Prenatal PBDEs and Neurodevelopment: Herbstman et al. Respond to Goodman et al. and to Banasik and Strosznajder by Herbstman, Julie B. et al.
Perspectives | Correspondence
A 468  v o l u m e 118 | number 11 | November 2010  •  Environmental Health Perspectives
Prenatal PBDEs and 
Neurodevelopment:  
Animal Studies and Human 
Health Assessment
doi:10.1289/ehp.1002753
Herbstman et al. (2010) reported an asso­
ciation between polybrominated diphenyl   
ether (PBDE) levels in cord blood and 
neuro  developmental effects in the children 
at specific ages. As a basis for their work, 
the authors cited several animal studies that 
reported causal relation  ships between prenatal 
exposure to PBDEs and develop  mental neuro­
toxicity. We are concerned that Herbstman 
et al.’s research suffers from investigator bias 
based on the reasons that follow. 
First, the U.S. Environmental Protection 
Agency (EPA) cosponsored an expert panel 
that refuted the experi  mental design employed 
in most of the studies cited by Herbstman 
et al. (2010) as a basis for their work. The 
U.S. EPA expert panel concluded that the 
experimental design failed to control for litter 
effects (Holson et al. 2008). 
Next, the potential for specific bromi­
nated flame retardants to cause develop  mental 
neurotoxicity has been evaluated under 
Good Laboratory Practice (GLP) standards 
and according to validated test guidelines. 
In each case, the claims of develop  mental 
neuro  toxicity from non­GLP, non­guideline 
studies were not reproducible (reviewed by 
Williams and DeSesso 2010). This is signifi­
cant because in Europe, data generated from 
studies performed under GLP and accord­
ing to validated test guidelines are consid­
ered the highest quality and most reliable 
(European Chemicals Agency 2008). Further, 
regulatory agencies in Europe and the United 
States seem to have shifted their stance on the 
non­GLP, non­guideline studies that have 
reported brominated flame retardant–induced 
develop  mental neuro  toxicity. For example, 
when the European Union issued their Risk 
Assessment Report on hexabromo  cyclo­
dodecane (HBCD), a brominated flame retar­
dant (European Chemicals Bureau 2008), 
they stated that 
… Eriksson et al. (2006) [i.e., the study reporting 
HBCD­induced developmental neurotoxicity] 
is not performed according to current guideline 
and GLP …. However, similar results on develop­
mental neurotoxicity have been published for 
decabromo  diphenyl  ether by the same authors using 
the same method [e.g., Viberg et al. (2003), which 
was cited by Herbstman et al. (2010)]. For deca­
bromodiphenylether it has been agreed to perform 
a new toxicokinetics/developmental neurotoxicity 
study according to a modified OECD guideline 
and GLP. The results from this new decabromo­
diphenylether study will serve as guidance on how 
to interpret the data from the Eriksson study, and 
may also serve as a basis on how to proceed with 
further testing of neurotoxicity. 
For two of the studies cited by Herbstman 
et al. (2010), which were used by the U.S. 
EPA for deriving reference doses for PBDEs 
153 and 209 (U.S. EPA 2008a, 2008b), the 
U.S. EPA was unable to obtain the raw data. 
However, when the raw data were obtained 
for the PBDE 209 study (i.e., Viberg et al. 
2003) by a third party, who subsequently pro­
vided the data to the U.S. EPA, the agency 
acknowledged that the data were not suit­
able for use with human health assessment 
(U.S. EPA 2010). 
We mention the above information 
because Herbstman et al. (2010) cited only 
animal studies that reported PBDE­induced 
developmental neurotoxicity as support for 
their work. Although the authors discussed 
one epidemiological study that reported find­
ings inconsistent with their own, Herbstman 
et al. (2010) reverted back to the positive ani­
mal studies as support for their work. They 
did not discuss or cite any animal studies   
that reported contradictory findings. This is 
significant because it may have introduced a 
formidable source of bias when Herbstman 
et al. (2010) were interpreting their results. 
The exclusion may also mislead the readership 
of EHP. 
M.B. has received a total of US$2,000 from 
the brominated flame retardant industry for his 
contribution to three publications in 2008–2009, 
but he received no form of remuneration for his 
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Prenatal PBDEs and 
Neurodevelopment:  
Accuracy of Assessment
doi:10.1289/ehp.1002748
Herbstman et al. (2010) measured eight poly­
brominated diphenyl ethers (PBDEs) in cord 
blood and reported that children of moth­
ers with higher cord blood concentrations 
of PBDEs 47, 99, and 100 scored lower on 
mental and physical development tests at 
12, 24, 36, and 72 months of age. Here, we 
raise several issues that limit the conclusions 
that may be drawn from their study.
In the study by Herbstman et al. (2010), 
only 210 cord blood specimens from 
329 mothers were available, and assessments 
were conducted for only 96–118 children at 
each age. Several congeners were measured 
in the study; overall, the percentage of indi­
vidual congeners below the limit of detection 
(LOD) ranged from 18.6% to 96.1%.  For 
congeners on which major assessments were 
conducted, the range of values < LOD was 
18.6–50.2%. Herbstman et al. (2010) did 
not state how many samples were < LOD 
for each assessment, so it is possible that the 
percentage was even higher and may have 
led to a large impact on the results, particu­
larly given the small sample size for each 
assessment. 
Herbstman et al. (2010) measured PBDEs 
in cord blood and maternal blood only once, 
but individual levels most likely changed over 
the course of the pregnancy and over the period 
when develop  mental assessments were con­
ducted. The median values were rela  tively low, 
and there was no reliable indication of inter­
individual variability, so even small changes 
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over time could have altered any observed 
exposure–response associations. In addition, 
the authors did not indicate how assessments 
of individual children changed over time. If 
different children contributed to associations at 
different ages, the reported findings may not be 
indicative of a causal role for PBDEs. Notably, 
most associations were found at earlier ages, 
suggesting that even if PBDEs were causal, 
effects were reversible.
Herbstman et al. (2010) reported that all 
PBDEs were correlated with one another, 
as were repeated develop  mental scores. Yet 
associations varied both among PBDEs for 
the same tests and among repeated tests for 
the same PBDEs. If PBDEs are truly causal 
and acting via similar mechanisms of action, 
results should be repeatable across PBDEs 
and repeated tests. This is not the case, thus 
suggesting that chance or some other factor 
(e.g., alcohol, caffeine, poor diet, methyl­
mercury, poly  chlorinated biphenyls) is a 
more likely explanation. In addition, all of 
the mothers in the study were pregnant and 
lived near the World Trade Center (WTC) 
on 11 September 2001. Given this proxim­
ity, there is no way of knowing whether other 
unmeasured exposures or other factors (e.g., 
psychological, behavioral) contributed to 
neuro  logical effects.
Herbstman et al. (2010) used the Bayley 
Scales of Infant Development, Second 
Edition (BSID­II) to measure develop  mental 
impairment, which is based on a mean ± SD 
of 100 ± 15 to define normal development 
(Bayley 1993). This means that in 68% of the 
standard population, scores ranged from 85 
to 115. The authors reported that through 
uni  variate analysis, the change in the BSID­II 
score from the 25th percentile of PBDE level 
to the 75th percentile was –5.57. This degree of 
change is well within the SD of the test, which 
makes it impossible to determine whether the 
relation  ship observed was due to PBDEs or 
simply the inter  individual variability inherent 
to the test. Because the authors did not assess 
the association between PBDE levels and those 
scoring outside the SD of the test (compared 
with those scoring within), it is impossible to 
determine whether a clinically significant asso­
ciation between PBDE cord blood levels and 
develop  mental impairment exists. Changes in 
IQ scores are not very meaningful unless they 
are put directly into context with the scoring 
ranges in the test design; Herbstman et al. did 
not provide much information as to the scores 
that were actually produced, though they 
implied that those from mothers with higher 
PBDE levels were somehow impaired when 
they may well have been normal.
Taken together, these factors prevent 
an accurate assessment of whether prenatal 
exposure to PBDEs is associated with adverse 
neuro  developmental effects.
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doi:10.1289/ehp.1002748R
In our article (Herbstman et al. 2010), we 
reported evidence showing that children 
who had higher cord blood concentrations 
of polybrominated diphenyl ethers (PBDEs) 
scored lower on tests of mental and motor 
development at 1–4 and 6 years of age. We 
initiated this work based on a large body of 
experi  mental research indicating that prenatal 
PBDE exposure has the potential to disrupt 
neuro  development. In their letter, Banasik and 
Strosznajder comment that the basis for our 
work may be biased because of experi  mental 
design flaws in the animal studies we cited. 
In the introduction of our paper, we cited an 
extensive review article in which Costa and 
Giordano (2007) carefully outlined a wide vari­
ety of toxicological evidence exploring the asso­
ciation between prenatal PBDE exposure and 
neurotoxicity. The authors cited both positive 
and negative animal studies and also reviewed 
in vitro studies and reports outlining endo­
crine­disrupting effects associated with PBDE 
exposure. We believe that we directed EHP 
readers to sufficient evidence that provides an 
adequate basis for our research question. Since 
our manuscript was accepted for publication, 
an additional in vitro study was published; that 
study (Schreiber et al. 2010) demon  strated that 
primary fetal human neural progenitor cells 
exposed to BDEs 47 and 99 had decreased 
migration distance and reduced differentia­
tion into neurons and oligo  dendrocytes. 
Taken together, the scientific literature pro­
vides adequate biological plausibility and raises 
substantial concern about the potential for 
PBDE­related develop  mental neuro  toxicity in 
humans. 
Additional comments from Goodman 
et al. in their letter raise the possibility that the 
number of samples below the limit of detec­
tion (LOD) in our study sample could be 
higher than in the full study population and 
could thereby effect the results. We explored 
this possibility and found that the number 
of study samples with PBDE levels < LOD 
ranged from 14% to 19% for BDE­47, 
40% to 50% for BDE­99, 27% to 34% for 
BDE­100 and 38% to 43% for BDE­153, 
depending on the testing age. These are not 
significantly different from the proportions of 
samples < LOD in the full study population. 
Goodman et al. also point out that PBDE 
concentrations in our study were measured at 
one point in time and were likely to change 
over the course of pregnancy and postnatally. 
It is true that little is known about changes in 
PBDE levels within individuals over time or 
the half­lives of lower brominated PBDEs in 
human serum. One study (Geyer et al. 2004) 
estimated that that the half­lives of BDEs 47, 
99, 100, and 153 range from 1.8 to 6.5 years 
We estimated prenatal PBDE exposure based 
on cord blood levels at delivery. If these esti­
mated half­lives are accurate and we assume 
that PBDE exposure is chronic, it is unlikely 
that there are substantial changes in concen­
trations over an approximately 9­month preg­
nancy. Although cord blood is adequate for 
assessing PBDE exposure during the prenatal 
and early postnatal periods, which are critical 
periods for neuronal differentiation and migra­
tion, we concur that it is possible that there 
are other windows of susceptibility that are not 
adequately represented by cord blood PBDE 
concentrations (Rice and Barone 2000). In the 
“Discussion” of our article, we noted the limita­
tion that we were not able to control for post­
natal PBDE exposure in our analyses. 
Goodman and al. ask whether different 
children contribute to the observed associa­
tions at different ages and assert that most 
associations were found at earlier ages, sug­
gesting that observed effects are reversible. 
We reported that repeated develop  mental Correspondence
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test scores within an individual were corre­
lated. We elected not to analyze the data using 
repeated measures because we used two dif­
ferent, age­appropriate neuro  developmental 
tests. These tests are correlated but may not 
be directly comparable because they measure 
slightly different neuro  develop  mental con­
structs. We disagree with the statement that 
associations were observed only at younger 
ages. Figure 1 of our article (Herbstman et al. 
2010) illustrates that in our study popula­
tion, the highest concentrations of exposure 
to prenatal PBDEs were associated with lower 
scores on nearly all neuro  develop  mental tests 
at nearly all time points. Although many, but 
not all, of these point estimates are statistically 
significant, nearly all are in the same direction. 
Therefore, we cannot understand how this 
suggests that the effects of prenatal exposure 
are reversible. 
Goodman et al. also posit that for cor­
related PBDEs to be causally associated with 
neuro  development, they must act via a similar 
mode of action (MOA). PBDE congeners are 
correlated, but they are of different chemi  cal 
configurations and sizes. We believe that it is 
overly simplistic to assume that they operate via 
the same MOA, which is why we chose not to 
combine them into one exposure metric in our 
analyses. 
Goodman et al. also raise the possibil­
ity that unmeasured confounders are a more 
likely explanation for the observed association 
between prenatal PBDEs and neuro  develop­
ment, given that the study participants were 
pregnant and lived near the World Trade 
Center (WTC) on 11 September 2001 (9/11). 
Our study population consisted of women who 
delivered at hospitals located near the WTC; 
only one­fourth of our study population actu­
ally lived within 2 miles of the WTC. As we 
stated in our article, we cannot rule out the 
potential impact of unmeasured confounders. 
This problem is not unique to our study. Our 
study population is distinctive in that the par­
ticipants were identified to explore the effects 
of prenatal exposure to the WTC after 9/11. 
Although we measured and controlled our anal­
yses for many potential confounders, we cannot 
rule out the possibility that some unmeasured 
factor could be associated with both prenatal 
PBDE exposure and neuro  develop  mental test 
scores and could have thereby confounded the 
observed associations. However, we do not 
understand the basis by which Goodman et al. 
conclude that unmeasured confounders are a 
more likely explanation. 
Finally, Goodman et al. assert that it is 
impossible to determine the clinical significance 
of the reported associations between prena­
tal PBDE levels and neuro  develop  mental test 
scores because the observed differences between 
exposure groups are smaller than the SD of the 
test instrument on a standardized population 
[for the Bayley Scales of Infant Development, 
Second Edition (BSID­II), SD = 15). We 
believe that Goodman et al. mis  interpreted 
the scores derived from the Bayley scales in the 
context of population research. It is true that 
the distribution of the Mental Development 
Index (MDI) and Psychomotor Development 
Index (PDI) scores have a mean ± SD of 
100 ± 15 (Bayley 1993); this is a useful guide­
line for interpreting the score for an individual 
child such that a child who scores < 1 SD of 
the standardized mean (score < 85) can be clini­
cally classified as having “delayed performance.” 
However, the differences we noted in our arti­
cle represent average difference in test scores 
between groups of children characterized based 
on their exposure levels. To illustrate our point, 
for BDE­100 at 36 months of age, the aver­
age test score for the highly exposed group is 
6.1 points lower than the average score for the 
group of children with lower exposure (control­
ling for confounders). This shift is both statisti­
cally significant and, if confirmed, biologically 
rele  vant on a population level. Furthermore, 
the magnitude of this effect may be cognitively 
and educationally meaningful, as has been illus­
trated in the lead literature, where the size of the 
adverse effect is similar.
Our study was a well­conducted, prospec­
tive, longitudinal cohort study that demon­
strated associations between prenatal PBDE 
exposure and adverse neuro    development. 
Given that this is the first study to report 
these associations in humans, we interpreted 
these results cautiously until they can be   
replicated in another study population. 
The authors declare that they have no actual or 
potential competing financial interests.
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Errata
In the review by Rohr and McCoy [Environ Health Perspect 118:20–32 (2010)], Orton 
et al. (2006) was cited on page 26 but was not included in the reference list. The reference 
is as follows:
Orton F, Carr JA, Handy RD. 2006. Effects of nitrate and atrazine on larval development and sexual 
differentiation in the northern leopard frog Rana pipiens. Environ Toxicol Chem 25:65–71.
Cao et al. [Environ Health Perspect 118:1332–1337 (2010)] have reported errors in their 
paper. On page 1333 in the second paragraph of “Statistical methods and data analy  sis,” 
the following sentence was omitted: 
Because length, weight, and head circumference were highly correlated with age (the pairwise Pearson  
correlation coefficients were 0.91, 0.84, and 0.83, respectively), they were not included in the model, but we 
combined length and weight as body mass index (BMI) and introduced it into the model.
In the fourth paragraph of that section, one of the covariates (BMI) was omitted.  
The corrected sentence is as follows:
These covariates were age, sex, BMI, urinary thiocyanate, urinary nitrate, and urinary iodide. 
In addition, in the footnote of Table 3, “LOD/16%” was incorrect. The corrected sentence 
is as follows: 
Adjusted for age; values < LOD were replaced by LOD/√2 –; 16% for perchlorate; 0% for iodide; 6% for 
thiocyanate; 14% for nitrate. Mixed linear models account for multiple measures in the same child.
In the editorial by Fontham and Trapido [Environ Health Perspect 118:A422–A423 
(2010)], one reference cited in the text was inadvertently omitted from the reference list. 
The reference for Grulich et al. (2007) is as follows:
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. 2007. Incidence of cancers in peo­
ple with HIV/AIDS compared with immunosuppressed transplant recipients: a meta­analysis.  
Lancet 370(9581):59–67.
EHP apologizes for the error.